Explore our brands

Our brands bring together the industry's most influential leaders and scientific experts, inspiring thought-provoking and insightful content that offers a unique perspective on R&D trends and challenges.
Contact
ADC Discovery & Development Logo

PART OF NEXTGEN BIOMED 2027

18 - 19 March 2027 | InterContinental London - The O2, London, UK

Programme Summary

Delve into the latest advances in ADC discovery & development, with leading experts exploring next-generation ADC design, linker & payload technologies, conjugation strategies, toxicity prediction and mitigation, therapeutic index optimisation, and preclinical & translational approaches to accelerate safer, more effective ADCs towards the clinic.

DAY TWO

Peptides & Oligonucleotides Keynote Address

Fernando Albericio, Professor, University of KwaZulu-Natal

Fernando Albericio is a Research Professor at the University of KwaZulu-Natal (South Africa) and Emeritus Professor of Organic Chemistry at the University of Barcelona (Spain) with 50 years of experience in peptide chemistry.
His major research interests cover practically all aspects of peptide synthetic methodology as well as the synthesis of peptides and small molecules with therapeutic activities (cancer and infectious diseases). Lastly, he was working on greening the solid-phase peptide synthesis processes. He has published more than 1000 scientific articles, filed more than 60 patents, and graduated more than 80 Ph.D. students.

2027 Highlights

Next-Generation ADC Design & Optimisation

Explore novel linker, payload and conjugation technologies, emerging ADC formats and strategies to maximise efficacy and therapeutic index.

Tackling Toxicity & Translation

Address toxicity mechanisms, safety, resistance and PK/PD while exploring advanced preclinical models and strategies to accelerate ADCs towards the clinic.

NextGen Biomed - What to Expect Exhibiting 3
NextGen Biomed - What to Expect Networking 1
1000

leading pharma, biotech, regulatory & academic delegates

700
pre-arranged 1-2-1 meetings, facilitating business growth
50
hours of presentations, discussions & interactive content
12
hours of networking breaks, including fireside chats & refreshments
NGB + LSX Combined Logo-1

Unlock the Latest News and Insights

Sign-up for our regular LifeScienceXchange newsletter to keep up to date with all things NextGen Biomed, direct to your inbox.

NGB Newsletter Icon-1

Agenda at a Glance

DAY ONE TRACK

Track 5: ADC Design, Validation & Optimisation to Enhance Their Therapeutic Potential

DAY TWO TRACK

Track 4: ADC Pre-Clinical & Translational Development

Featured Speakers for ADC Development 2027

Annarita Di Tacchio
Research Scientist ,
AstraZeneca
Christian Rohlff
CEO,
Oxford Biotherapeutics
Jamie Baker
Professor of Chemistry,
University College London
Krzysztof Brzózka
CSO,
Ryvu Therapeutics
Lorenzo Albertazzi
Associate Professor TU/e Department of Biomedical Engineering,
Eindhoven University of Technology
Mariusz Olejniczak
CEO,
WPD Pharmaceuticals
Michael Wallington
Director, Oncology RWE & Epidemiology,
Pfizer
Paul Sauter
Senior Director Chemistry & Bioconjugation,
VERAXA Biotech GmbH
Ruud Coumans
Director of Protein Chemistry and Project Leader Antibody-Drug Conjugates,
Byondis

Interested in Sponsoring NextGen Biomed?

Become a driving force in accelerating the next generation of biologics and immunotherapy medicines to patients. NextGen Biomed offers a unique platform to enhance your brand visibility and connect with thousands of pharma, biotech, and R&D experts. Our branded event opportunities, immersive experiences, and content services enable you to engage, educate, and collaborate with the community shaping the future of biomedicine today.

Register Now

Be part of the new wave of Biomed R&D innovation

Partner with us

Become a driving force in accelerating the next generation of ADC medicines to patients